Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Chk2 inhibitor
DRUG CLASS:
Chk2 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
ACR-368 (25)
PHI-101 (12)
AZD-7762 (1)
PV-1019 (0)
ACR-368 (25)
PHI-101 (12)
AZD-7762 (1)
PV-1019 (0)
›
Associations
(38)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
ACR-368
Sensitive: B - Late Trials
ACR-368
Sensitive
:
B
BRCA1 mutation
Ovarian Serous Adenocarcinoma
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib + ACR-368
Sensitive: C2 – Inclusion Criteria
olaparib + ACR-368
Sensitive
:
C2
olaparib + ACR-368
Sensitive: C2 – Inclusion Criteria
olaparib + ACR-368
Sensitive
:
C2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
PHI-101
Sensitive: C2 – Inclusion Criteria
PHI-101
Sensitive
:
C2
PHI-101
Sensitive: C2 – Inclusion Criteria
PHI-101
Sensitive
:
C2
BRCA2 mutation
Ovarian Serous Adenocarcinoma
BRCA2 mutation
Ovarian Serous Adenocarcinoma
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
BRCA1 mutation
Ovarian Serous Adenocarcinoma
BRCA1 mutation
Ovarian Serous Adenocarcinoma
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
ACR-368
Sensitive: C2 – Inclusion Criteria
ACR-368
Sensitive
:
C2
CCNE1 amplification
Ovarian Cancer
CCNE1 amplification
Ovarian Cancer
ACR-368 + LY3300054
Sensitive: C3 – Early Trials
ACR-368 + LY3300054
Sensitive
:
C3
ACR-368 + LY3300054
Sensitive: C3 – Early Trials
ACR-368 + LY3300054
Sensitive
:
C3
PIK3CA mutation
Solid Tumor
PIK3CA mutation
Solid Tumor
ACR-368 + LY3023414
Sensitive: C3 – Early Trials
ACR-368 + LY3023414
Sensitive
:
C3
ACR-368 + LY3023414
Sensitive: C3 – Early Trials
ACR-368 + LY3023414
Sensitive
:
C3
SRSF2 mutation
Acute Myelogenous Leukemia
SRSF2 mutation
Acute Myelogenous Leukemia
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
olaparib + ACR-368
Sensitive: C3 – Early Trials
olaparib + ACR-368
Sensitive
:
C3
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
FLT3 wild-type
Acute Myelogenous Leukemia
FLT3 wild-type
Acute Myelogenous Leukemia
PHI-101
Sensitive: C3 – Early Trials
PHI-101
Sensitive
:
C3
PHI-101
Sensitive: C3 – Early Trials
PHI-101
Sensitive
:
C3
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
PHI-101
Sensitive: C3 – Early Trials
PHI-101
Sensitive
:
C3
PHI-101
Sensitive: C3 – Early Trials
PHI-101
Sensitive
:
C3
BRCA1 3363delGAAA
Triple Negative Breast Cancer
BRCA1 3363delGAAA
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA1 5396insC
Triple Negative Breast Cancer
BRCA1 5396insC
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA2 5396insC
Triple Negative Breast Cancer
BRCA2 5396insC
Triple Negative Breast Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
CACNA1D E953D
Triple Negative Breast Cancer
CACNA1D E953D
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
TP53 R273H
Triple Negative Breast Cancer
TP53 R273H
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
PTEN V85
Triple Negative Breast Cancer
PTEN V85
Triple Negative Breast Cancer
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
ACR-368
Resistant: D – Preclinical
ACR-368
Resistant
:
D
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L
Acute Myelogenous Leukemia
FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3-ITD mutation + FLT3 F691L
Acute Myelogenous Leukemia
FLT3-ITD mutation + FLT3 F691L
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3-ITD mutation + FLT3 D835Y
Acute Myelogenous Leukemia
FLT3-ITD mutation + FLT3 D835Y
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
BRCA2 deletion
Prostate Cancer
BRCA2 deletion
Prostate Cancer
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
ACR-368
Sensitive: D – Preclinical
ACR-368
Sensitive
:
D
BRCA2 mutation
Ovarian Serous Adenocarcinoma
BRCA2 mutation
Ovarian Serous Adenocarcinoma
ACR-368 + LY3023414
Sensitive: D – Preclinical
ACR-368 + LY3023414
Sensitive
:
D
ACR-368 + LY3023414
Sensitive: D – Preclinical
ACR-368 + LY3023414
Sensitive
:
D
FLT3 D835A
Acute Myelogenous Leukemia
FLT3 D835A
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3 840GS
Acute Myelogenous Leukemia
FLT3 840GS
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3 F691L
Acute Myelogenous Leukemia
FLT3 F691L
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3 N676D
Acute Myelogenous Leukemia
FLT3 N676D
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
FLT3 A627T
Acute Myelogenous Leukemia
FLT3 A627T
Acute Myelogenous Leukemia
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
PHI-101
Sensitive: D – Preclinical
PHI-101
Sensitive
:
D
BCL2L1 overexpression
Pancreatic Cancer
BCL2L1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login